Debt Investors

Funding strategy

  • The Board reviews the Company’s ongoing liquidity risks annually as part of the planning process and on an ad-hoc basis.
  • The Board considers short-term requirements against available sources of funding, taking into account forecast cash flows.
  • The Company manages liquidity risk by maintaining access to a number of sources of funding which are sufficient to meet anticipated funding requirements.
  • Specifically, the Company uses US commercial paper, committed bank facilities and cash resources to manage short-term liquidity.
  • The Company has $3bn of revolving committed credit facilities provided by 8 relationship banks.  These facilities were undrawn as at 30 September 2017 and will mature in April 2022.
  • The Company maintains strong access to the capital markets for long-term funding through an established Euro Medium Term Note (EMTN) programme and a SEC registered shelf programme.
  • These different funding programmes ensure that the Company has sufficient flexibility when choosing the maturity, currency, interest rate (fixed/floating), and geographical mix of investors.

A summary of utilisation from the Company’s debt programmes as at 30 September 2017 is shown in the table below.


Programme Last updated Valid to Limit Rating (Moody's/ S&P) Utilisation as at 30/09/2017

US Commercial Paper



USD 15bn

A-2 / P-2

USD 0.3bn

Euro Medium Term Note Programme



USD 5bn

A3 / BBB+

USD 3.9bn

SEC Registered Shelf Programme




A3 / BBB+

USD 12.8bn

Debt maturity profile

AstraZeneca chooses to hold a significant cash balance to meet operational funding needs. Gross cash and investments position as at 30 September 2017 was $5.7bn

FX converted at September 2017 spot rates (USD/EUR 0.8474; USD/GBP 0.7466)

Outstanding bonds

Below is a summary of the bonds issued or guaranteed by AstraZeneca PLC as at 30 September 2017, sorted by maturity date.

Currency Notional Issue date Maturity date Coupon Frequency ISIN
USD 1,000 16-Nov-15 16-Nov-18 1.75% Semi-annual US046353AH15
USD 400 16-Nov-15 16-Nov-18 3m Libor + 0.53% Quarterly US046353AJ70
USD 1,000 18-Sep-12 18-Sep-19 1.95% Semi-annual US046353AF58
USD 1,600 16-Nov-15 16-Nov-20 2.375% Semi-annual US046353AK44
EUR 500 12-May-16 12-May-21 0.25% Annual XS1411403709
EUR 750 24-Nov-14 24-Nov-21 0.875% Annual XS1143486865
USD 250 12-Jun-17 10-Jun-22 3m Libor + 0.62% Quarterly US046353ap31
USD 1,000 12-Jun-17 12-Jun-22 2.375% Semi-annual US046353AQ14
USD 288 15-Nov-93 15-Nov-23 7.00% Semi-annual US98934KAB61
EUR 900 12-May-16 12-May-24 0.75% Annual XS1411404855
USD 2,000 16-Nov-15 16-Nov-25 3.375% Semi-annual US046353AL27
USD 750 12-Jun-17 12-Jun-27 3.125% Semi-annual US046353AN82
EUR 800 12-May-16 12-May-28 1.25% Annual XS1411404426
GBP 350 13-Nov-07 13-Nov-31 5.75% Annual XS0330497149
USD 2,750 12-Sep-07 15-Sep-37 6.45% Semi-annual US046353AD01
USD 1,000 18-Sep-12 18-Sep-42 4.00% Semi-annual US046353AG32
USD 1,000 16-Nov-15 16-Nov-45 4.375% Semi-annual US046353AM00

Credit ratings

AstraZeneca PLC aims to maintain a strong, investment grade credit rating.  The Company has solicited credit ratings from Moody’s and S&P, which are assigned as:

Short-term rating P-2 A-2
Long-term rating A3 BBB+
Outlook Negative Stable

Key contacts at the respective agencies are:


Analyst: Knut Slatten

Phone: 33-1-5330-1077


Analyst: Marketa Horkova

Phone: (44) 20-7176-3743

Treasury risk management policies

The Company operates with a centralised Treasury structure so that key Treasury risks are managed at a Group level.

Investment policy

  • Security and liquidity
  • Financial counterparty limits

Foreign Exchange Policy

  • Foreign Exchange exposures managed centrally
  • Transactional currency exposures substantially hedged

Interest Rate Policy

  • Level of floating rate debt matched to cash
  • Significant portion of financial liabilities at fixed interest rates

Credit Risk

  • Cash managed centrally
  • Derivatives positions fully collateralised

Liquidity Policy

  • Prudent level of available cash and unutilised credit facilities
  • Group funding centrally managed

Contact Us

Craig Marks

Senior Investor Relations Director, Finance/Fixed Income/M&A

Brendan Boucher

Group Treasurer

  • Annual Reports

    Our Annual Report provides a wide range of information about our global business.

  • Our Pipeline

    Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development

  • Shareholder FAQs

    Answers to frequently asked shareholder questions.